Clozapine-associated secondary antibody deficiency.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Clozapine has recently been described as a novel cause of secondary antibody deficiency (SAD), associated with long-term therapy. Here we critically review the evidence linking clozapine use to an increased infection risk, describe immunological alterations, and discuss potential mechanisms.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Curr Opin Allergy Clin Immunol

Title: Current opinion in allergy and clinical immunology

Publisher: Ovid Technologies (Wolters Kluwer Health)

ISSN (Electronic): 1473-6322

ISSN (Print): 1473-6322

Publication date (Electronic): December 2019

Volume: 19

Issue: 6

Affiliations

[1 ] Immunodeficiency Centre for Wales, University Hospital of Wales.

[2 ] Division of Infection & Immunity, Tenovus Institute, Cardiff University, Cardiff, UK.

[3 ] Department of Translational Medical Sciences, Allergy and Clinical Immunology, Center for Basic and Clinical Immunology Research, University of Naples Federico II, Naples, Italy.

Article

DOI: 10.1097/ACI.0000000000000592

PubMed ID: 31567398

SO-VID: 5d07c0eb-0409-4cca-9b97-96c8f61375b9

History

Data availability:

Comments

Comment on this article

scite_

Cited by 18

See all cited by